Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)
Today, Leerink Swann reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ:ALXN) with a price target of $182.00.
There are 5 hold ratings, 17 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy (Score: 2.83) with a consensus target price of $158.41 per share, a potential 10.92% upside.
Some recent analyst ratings include
- 9/25/2017-Leerink Swann Reiterated Rating of Buy.
- 9/14/2017-Royal Bank Of Canada initiated coverage with a Outperform rating.
- 9/13/2017-Deutsche Bank AG Reiterated Rating of Buy .
- 9/13/2017-SunTrust Banks, Inc. Reiterated Rating of Buy.
- 9/13/2017-BMO Capital Markets Reiterated Rating of Outperform.
- 9/5/2017-J P Morgan Chase & Co Upgrade from a “Neutral ” rating to a ” Overweight” rating.
- 8/16/2017-Evercore ISI initiated coverage with a In rating.
Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 94.17%.
- On 9/5/2017 Ann M Veneman, Director, sold 835 with an average share price of $145.81 per share and the total transaction amounting to $121,751.35. View SEC Filing
- On 9/5/2017 Julie O’neill, EVP, sold 4,375 with an average share price of $145.44 per share and the total transaction amounting to $636,300.00. View SEC Filing
- On 8/28/2017 Julie O’neill, EVP, sold 11,160 with an average share price of $140.00 per share and the total transaction amounting to $1,562,400.00. View SEC Filing
- On 7/31/2017 Ann M Veneman, Director, sold 700 with an average share price of $137.74 per share and the total transaction amounting to $96,418.00. View SEC Filing
- On 6/15/2017 Bros. Advisors Lp Baker, Director, bought 660,779 with an average share price of $117.33 per share and the total transaction amounting to $77,529,200.07. View SEC Filing
- On 6/14/2017 Bros. Advisors Lp Baker, Director, bought 1,348,955 with an average share price of $116.32 per share and the total transaction amounting to $156,910,445.60. View SEC Filing
- On 6/14/2017 Ludwig Hantson, CEO, bought 10,000 with an average share price of $116.72 per share and the total transaction amounting to $1,167,200.00. View SEC Filing
Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at with shares trading hands.